Treating cancer by blocking the interaction of TIM-3 and its ligand
AssigneeTrueBinding, Inc.
InventorsDongxu Sun, Yan Wang
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of activating immune response and/or treating cancer in a patient comprising administering to the patient a Gal3:TIM-3 inhibitor that interferes with the interaction between Gal3 and TIM-3, where said inhibitor is administered in an amount sufficient to activate immune response. Also provided are a humanized anti-Gal3 antibodies that can block the interaction between Gal3 and TIM3 and methods of using the anti-Gal3 antibody to treat cancer. Methods for determining if a patient's cancer is suitable for treatment with a Gal3:TIM-3 inhibitor and methods for selecting compounds that can block interaction between Gal3 and TIM-3, activating immune response and/or treating cancer are also provided.
Claims15
A method of activating an immune response in a patient with a cancer, comprising:
- administering to the patient an effective amount of an anti-Gal3 antibody that interferes with the interaction between Gal3 and TIM-3, wherein the anti-Gal3 antibody comprises
- (1) a light chain variable region comprising a complementary determining region (CDR) L1, a CDR L2, and a CDR L3 and
- (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3,
- wherein
- the CDR L1 comprises the amino acid sequence of SEQ ID NO:17,
- the CDR L2 comprises the amino acid sequence of SEQ ID NO:18,
- the CDR L3 comprises the amino acid sequence of SEQ ID NO:19,
- the CDR H1 comprises the amino acid sequence of SEQ ID NO:9,
- the CDR H2 comprises the amino acid of SEQ ID NO:10, and
- the CDR H3 comprises the amino acid sequence of SEQ ID NO:11;
- wherein the Gal3 is overexpressed on cells in a tumor microenvironment,
- the TIM-3 is expressed on immune cells, and
- the effective amount is sufficient to activate the immune response in the patient
- wherein the anti-Gal3 antibody is a humanized antibody or a human antibody.
A method of activating immune response in a patient comprising administering to the patient an anti-Gal3 antibody that interferes with the interaction between Gal3 and TIM-3,
- wherein said anti-Gal3 antibody is administered in an amount sufficient to activate immune response,
- wherein the anti-Gal3 antibody is a humanized antibody;
- and
- wherein the anti-Gal3 antibody comprises
- (1) a light chain variable region comprising a complementary determining region (CDR) L1, a CDR L2, and a CDR L3 and
- (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3,
- wherein
- the CDR L1 comprises the amino acid sequence of SEQ ID NO:17,
- the CDR L2 comprises the amino acid sequence of SEQ ID NO:18,
- the CDR L3 comprises the amino acid sequence of SEQ ID NO:19,
- the CDR H1 comprises the amino acid sequence of SEQ ID NO:9,
- the CDR H2 comprises the amino acid of SEQ ID NO:10, and
- the CDR H3 comprises the amino acid sequence of SEQ ID NO:11.
A method of activating immune response in a patient comprising administering to the patient an antibody, wherein the antibody includes a means for inhibiting the interaction between Gal3 and TIM-3, wherein the means for inhibiting the interaction comprises a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3, and a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein
- the CDR L1 comprises the amino acid sequence of SEQ ID NO:17,
- the CDR L2 comprises the amino acid sequence of SEQ ID NO:18,
- the CDR L3 comprises the amino acid sequence of SEQ ID NO:19,
- the CDR H1 comprises the amino acid sequence of SEQ ID NO:9,
- the CDR H2 comprises the amino acid of SEQ ID NO:10, and
- the CDR H3 comprises the amino acid sequence of SEQ ID NO:11.
Dependencies are inferred from the claim text.